Physician profile
Steven K Sacket
NPI 1538196886
$17,488.39
in general payments reported to CMS, 2019-2025
59 companies · $3,130 in 2025
The $3,130 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,252 · 2020: $1,901 · 2021: $3,177 · 2022: $2,311 · 2023: $2,367 · 2024: $2,350 · 2025: $3,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,753 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,753.15 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,619.88 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,573.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,534.68 | 2019-2025 | |
| Amgen INC. | $1,213.19 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $1,165.11 | 2020-2025 | Linzess, Viberzi, Ubrelvy |
| Glaxosmithkline, LLC. | $1,014.96 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $813.69 | 2019-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $813.17 | 2019-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $776.91 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $726.04 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $668.10 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $568.78 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $485.66 | 2019-2023 | Belsomra, Steglatro, Januvia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $422.12 | 2019-2025 | Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $355.43 | 2020-2024 | Trintellix |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Sacket listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.